Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

  • ID: 3691109
  • Drug Pipelines
  • 226 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • CerRx, Inc.
  • Incyte Corporation
  • Onxeo SA
  • Seattle Genetics, Inc.
  • MORE
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

Summary

‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • CerRx, Inc.
  • Incyte Corporation
  • Onxeo SA
  • Seattle Genetics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Peripheral T-Cell Lymphomas (PTCL) Overview

Therapeutics Development

Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview

Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies

Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development

AB Science SA

Affimed Therapeutics AG

Bayer AG

Celgene Corporation

CerRx, Inc.

Chipscreen Biosciences Ltd

Eisai Co., Ltd.

Incyte Corporation

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Mundipharma International Ltd

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Pfizer Inc.

Rhizen Pharmaceuticals S.A.

Seattle Genetics, Inc.

Solasia Pharma K.K.

Spectrum Pharmaceuticals, Inc.

TG Therapeutics, Inc.

Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AFM-13 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

belinostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CS-055 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

darinaparsin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

denileukin diftitox - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fenretinide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

forodesine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mitoxantrone hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NL-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

romidepsin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RP-6530 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TGR-1202 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tipifarnib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates

Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects

Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products

Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones

Featured News & Press Releases

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan

Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015

Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP

Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma

Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma

Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology

May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China

Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma

Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016

Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
Affimed Therapeutics AG
Bayer AG
Celgene Corporation
CerRx, Inc.
Chipscreen Biosciences Ltd
Eisai Co., Ltd.
Incyte Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Mundipharma International Ltd
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Pfizer Inc.
Rhizen Pharmaceuticals S.A.
Seattle Genetics, Inc.
Solasia Pharma K.K.
Spectrum Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll